Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

21 results about "Cyclin-dependent kinase" patented technology

Cyclin-dependent kinases (CDKs) are the families of protein kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. They are present in all known eukaryotes, and their regulatory function in the cell cycle has been evolutionarily conserved. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase. CDKs phosphorylate their substrates on serines and threonines, so they are serine-threonine kinases. The consensus sequence for the phosphorylation site in the amino acid sequence of a CDK substrate is [S/T*]PX[K/R], where S/T* is the phosphorylated serine or threonine, P is proline, X is any amino acid, K is lysine, and R is arginine.

Composition for predicting clinical stage of alzheimer's disease and kit using the same

The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of Nos1 (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY

Use of a protein kinase inhibitor for the preparation of a medicament for inhibiting uterine leiomyosarcoma

Disclosed is an application of a protein kinase inhibitor in preparation of a medicine for inhibiting uterine leiomyosarcoma, wherein the protein kinase inhibitor can effectively inhibit tumor growth in vitro and in vivo, and has better efficacy and safety compared with traditional chemotherapy. The protein kinase is one of the following: Wee1-like protein kinase, cyclin-dependent kinase 1, serine / threonine protein kinase 1 and serine / threonine protein kinase ATR.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Compositions and methods for delivering cyclin-dependent kinase-like 5 protein

PCT designated stageWO2026096600A1Genetic material ingredientsNucleic acid vectorCDKL5Epileptic encephalopathy
The disclosure relates to adeno-associated (AAV) particles comprising viral genomes encoding cyclin-dependent kinase-like 5 (CDKL5) proteins and peptides, compositions comprising said AAV particles, and methods for making and delivering said AAV particles to a cell or subject. The AAV particles, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a CDKL5 deficiency disorder (CDD), developmental and epileptic encephalopathy 2, atypical Rett syndrome, and / or other CDKL5-related disorders or at least one symptom thereof.
Owner:NEUROCRINE BIOSCIENCES INC +1

Combination therapy of CDK7 inhibitors with other Anti-cancer therapies

PendingUS20260041693A1Antineoplastic agentsRadiosensitized materialsAnti-Carcinogenic AgentsOncology
The present disclosure relates to combinations of cyclin-dependent kinase 7 (CDK7) inhibitors and other therapeutic treatments, in particular other anti-cancer agents, and uses of such combination(s) in the treatment of cancers.
Owner:QURIENT CO LTD

CDK9 inhibitor as well as preparation method and application thereof

The invention provides a CDK9 inhibitor as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The compound provided by the invention is an effective cyclin dependent kinase (CDK) inhibitor and has a structure as shown in a formula I. The compound disclosed by the invention has an excellent inhibition effect on CDK9 / cyclin T1, and has a wide application prospect in the aspect of preparing a CDK9 inhibitor.
Owner:CHENGDU CYNOGEN BIO-PHARM TECH CO LTD

Combination therapy for cancer with BRAF mutations

The present invention provides a combination therapy for treating a cancer having a BRAF mutation, the combination therapy comprising administering to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen activated protein kinase (MEK) 1 / 2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4 / 6 inhibitor. Compositions and kits related to the combination therapy are also provided.
Owner:COTHERA BIOSCIENCE INC

P21 Expressing Monocytes for Cancer Cell Therapy

Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.
Owner:LINSTITUT GUSTAVE ROUSSY (34 PART INTEREST) +2

Methods for diagnosing homologous recombination defects in human tumors

PendingCN121002199AMicrobiological testing/measurementHuman tumorAssociated phenotype
The present invention relates to improved methods for diagnosing homologous recombination deficiency (HRD) in tumors. The method according to the invention comprises, inter alia, assessing the number of large scale genomic variations (LGAs) by obtaining a copy number variation (CNA) profile by low coverage whole genome sequencing (sWGS) in a tumor sample, and determining an LGA score corresponding to the number of LGAs adjusted according to the genomic complexity of the tumor and the presence of one or both markers, the marker is selected from the following groups of markers: (1) a cyclin dependent kinase 12 (CDK12) mutation related phenotype with multiple interstitial gains in a CNA spectrum, (2) cyclin E1 (CCNE1) amplification, (3) human epidermal growth factor receptor-2 (HER2) amplification and (4) a multifocal amplification phenotype.
Owner:INSTITUT CURIE +1

Immortalized bovine muscle-derived stem cell line as well as construction method and application thereof

The invention discloses an immortalized bovine muscle-derived stem cell line as well as a construction method and application thereof, and belongs to the technical field of stem cells and biological cell lines. The bovine muscle-derived stem cell line is characterized in that telomerase reverse transcriptase (TERT) and cyclin dependent kinase (CDK) genes are overexpressed in a mode of lentivirus packaging and infection, a cell strain which is single in source and stably expresses a target gene is obtained through monoclonal screening, gene verification and functional verification, and the verification shows that the cell line overexpresses the CDK4 and TERT genes, so that the cell line can be used for preparing the bovine muscle-derived stem cell line with the stable expression of the target gene. The monoclonal cell strain can stably proliferate and maintain good differentiation characteristics. The immortalized bovine muscle-derived stem cell line is prepared, and a good seed cell resource is reserved for commercialized production of cultured meat.
Owner:NANJING JOES FUTURE FOOD TECH CO LTD

Engineered extracellular vesicles and uses thereof

Described herein are engineered extracellular vesicles (EVs) comprising at least one cyclin-dependent kinase (CDK) protein. Also provided are methods using the EVs to treat a wound, e.g., a diabetic wound.
Owner:RGT UNIV OF CALIFORNIA

Compositions and methods for delivering cyclin-dependent kinase-like 5 protein

PCT designated stageWO2026096611A1Genetic material ingredientsNucleic acid vectorDiseaseEpileptic encephalopathy
The disclosure relates to polynucleotides, e.g., viral genomes, encoding cyclin-dependent kinase-like 5 (CDKL5), vectors, e.g., adeno-associated virus (AAV) particles, comprising said polynucleotides, compositions comprising said polynucleotides or vectors, and methods for making or delivering to a cell or subject. The polynucleotides, vectors, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a CDKL5 deficiency disorder (CDD), developmental and epileptic encephalopathy 2, atypical Rett syndrome, and / or other CDKL5-related disorders, or at least one symptom thereof.
Owner:NEUROCRINE BIOSCIENCES INC

Compound functioning as CDK4 protein kinase inhibitor and use thereof

The present invention relates to a compound functioning as a CDK4 kinase inhibitor and to the use thereof. Specifically, the compound of the present invention has a chemical structure as represented by formula I or formula II, wherein each group and substituent are defined as described in the description. The compound of the present invention can function as an inhibitor of cyclin-dependent kinases (CDK) to treat or prevent proliferative diseases (such as cancer) and especially to regulate and treat related diseases caused by abnormal CDK4 activity.
Owner:TYK MEDICINES INC

Combined use of KAT6 inhibitor

Provided in the present disclosure is the combined use of a KAT6 inhibitor. Specifically, the present invention relates to the use of a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating breast cancer in combination with the following: a) a cyclin-dependent kinase 4 (CDK4) inhibitor; b) an antiestrogen drug; or c) a CDK4 inhibitor and an antiestrogen drug.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1

Compound used as CDK4 protein kinase inhibitor and application thereof

The invention relates to a compound used as a CDK4 kinase inhibitor and application thereof. Specifically, the compound provided by the invention has a chemical structure shown as a formula I or a formula II, and the definitions of all groups and substituent groups are described in the specification. The compound provided by the invention can be used as an inhibitor of cyclin-dependent kinase (CDK), is used for treating or preventing proliferative diseases (such as cancer), and is particularly used for regulating and treating related diseases caused by abnormal activity of cyclin-dependent kinase (CDK4).
Owner:TYK MEDICINES INC

Compound used as CDK4 kinase inhibitor and application thereof

The invention relates to a compound used as a CDK4 kinase inhibitor and application thereof. Specifically, the compound provided by the invention has a structure shown as a formula I or a formula II, and the definitions of all groups and substituent groups are described in the specification. The compound provided by the invention can be used as an inhibitor of cyclin-dependent kinase (CDK4), is used for treating or preventing proliferative diseases (such as cancers), and is particularly used for regulating and treating related diseases caused by abnormal activity of the cyclin-dependent kinase (CDK4). Formula I and formula II
Owner:TYK MEDICINES INC

Compounds, compositions, and methods of use thereof

The present disclosure relates to compounds that bind to and / or degrade one or more cyclin dependent kinases, as well as pharmaceutical compositions comprising the compounds disclosed herein, and methods for treating diseases, disorders, and conditions mediated, at least in part, by cyclin dependent kinases.
Owner:PLEXIUM INC

Anilino-pyrazole derivatives, compositions and methods thereof

PendingCN122459304ADiseasePharmaceutical drug
The present invention provides novel anilino-pyrazole derivatives as inhibitors of cyclin-dependent kinase 2 (CDK2). The invention also provides pharmaceutical compositions comprising the compounds and methods for their use in treating various conditions, diseases and disorders associated with or related to CDK2 activity or to abnormal cell growth, such as tumor growth and cancer.
Owner:ENSEM THERAPEUTICS INC